The order in which these stories are arriving matters more than any one of them alone. Cosmo holds the only US filing anyone has put on a calendar, a topical clascoterone built on the same active ingredient it already sells as the acne product Winlevi [6], and its Zurich-listed shares have been weighed down by the success of its American competitors [4][5]. Absci's ABS-201 is an early-stage, AI-designed injection whose first interim data has not landed [3]. Veradermics, which had the good sense to take the ticker MANE, has done roughly six times money in about six months [1][5]. Distance from a regulatory decision is worth more right now than proximity to one, which ranks the duration of a story above the date of a filing.
Then the arithmetic. Jefferies puts $3 billion of global sales on Cosmo's male hair-loss therapy, conditioned in the brokerage's own words on a capable commercial partner being found [7]; set that against the 50 million American men and 30 million American women with pattern hair loss [8], 80 million people [1], and it is $37.50 a head a year [2], with the entire global number credited to one country. Assume a cash-pay course at $600 a year, and that assumption is mine rather than Jefferies', and the forecast describes about five million users, some 6% of the affected population [3]. The partner in that sentence also has to be paid out of the same revenue line [7], so Cosmo ends up collecting only a slice of that $3 billion, not the full figure.
Cash pay is the whole argument, and Jefferies' Roger Song makes the strongest version of it: hair-loss patients stack prescription and over-the-counter products precisely because they are paying themselves, which is why the space can hold more than one winner [14]. Something close to 28 years without a new approval [4] has left the field to minoxidil, linked to heart palpitations, and finasteride, known to lower sex drive [10], and Needham's Gil Blum points out that people already fly to Turkey to have hair moved around their heads [21]. That is about as clean a revealed-preference test as this industry offers. Veradermics' tablet minoxidil read out positive in men in April and in women with thinning hair in July, and could become the first approved pill for female-pattern loss [15].
So, probably wrong, but I read the group as fully priced on approval and barely priced on elasticity, because a plane ticket to Istanbul tells you what the most motivated buyers will pay and nothing about the eightieth million. The view is also unfalsifiable for a while, since new medicines are more than a year from US shelves [11], and the comparison being drawn took Eli Lilly past a $1 trillion market value and made Novo Nordisk briefly Europe's most valuable company [18], which is the payoff getting extrapolated onto a cosmetic indication. What would prove me wrong is a launch with a price that holds and a refill rate to match; what would harden the view, or rather the more interesting version of it, is a Cosmo partnership signed at economics implying the partner does not believe the $3 billion either. Capital sitting at six times entry in MANE stays out of the reimbursed indications, where a payer, for all the fights it picks, sets a floor.
